ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Brilinta significantly reduced rate of composite of stroke and death in THALES trial
July 21, 2020Detailed results from the positive Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with daily aspirin for 30 days, reduced the rate of the primary composite endpoint of stroke and death by 17% (HR 0.83 ...
Pharma Sources Insight January 2025
